Novogene Enters Korea, Sparking Genome Data Fears
Expansion of a Chinese Genomics Firm in South Korea A China-based genome analysis firm, Novogene, has taken a significant step by establishing a wholly owned subsidiary, Novogene Korea, in June. This move marks the company's formal entry into the South Korean market. As one of the top five global leaders in genome sequencing, Novogene is leveraging its expertise to target domestic hospitals and research institutions. The company is offering discounts ranging from 20% to 30%, aiming to attract clients through competitive pricing. However, this expansion has raised concerns among experts. The genetic data involved contains sensitive biological information about South Koreans. If such data is transferred overseas, it could pose a national security risk. For instance, if a foreign biotech company were to identify diseases that South Koreans are particularly vulnerable to and develop treatments ahead of others, the country could face a situation similar to the COVID-19 pandemic, where...